Bausch + Lomb faced challenges in the fourth quarter, leading to a widened net loss due to increased interest and product launch expenses. Despite this setback, the eye-health company exceeded analyst expectations with strong revenue performance across its segments.

Financial Overview

  • Reported net loss of $54 million, or 15 cents per share, compared to a loss of $1 million in the same period last year.
  • Adjusted earnings stood at 24 cents per share, surpassing analysts' projected decline to 17 cents per share.
  • Revenue increased to $1.17 billion from $996 million, outperforming anticipated growth to $1.11 billion.

Segment Performance

  • Pharmaceutical unit saw significant growth, rising by 67% to $307 million.
  • Vision care, the largest segment, increased by 8% to $662 million.
  • Surgical segment rose by 9% to $204 million.

Future Outlook

Bausch + Lomb anticipates full-year revenue growth between 12% and 14%, reaching $4.6 billion to $4.7 billion in constant currency terms. Adjusted earnings before interest, taxes, depreciation, and amortization are expected to range from $840 million to $890 million, marking an improvement from the $738 million achieved in 2023.

CEO Statement

"We exceeded our revenue growth expectations in the fourth quarter of 2023, which sets a positive trajectory for the year ahead," stated Chief Executive Brent Saunders.

The company remains focused on navigating challenges and driving sustainable growth in the coming year.

Adriano Marchese

HSBC Quarterly Profit Decline

ChargePoint Stock Outlook

Leave A Reply

Your email address will not be published. Required fields are marked *